IL‐1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
- 3 November 2006
- journal article
- review article
- Published by Wiley in FEBS Letters
- Vol. 580 (27), 6289-6294
- https://doi.org/10.1016/j.febslet.2006.10.061
Abstract
Interleukin-1 receptor antagonist (IL-1ra) has been shown to play a crucial role in the prevention of various inflammatory diseases. There is also convincing evidence that IL-1ra is able to counteract inflammatory effects of IL-1 members implicated in insulin resistance and diabetes. However, the use of knock-out animal models provides evidence to the contrary and the role of IL-1ra in obesity-linked anomalies remains controversial. This minireview gets an insight into recent findings on the implication of IL-1ra and its gene polymorphism in diabetes and obesity, discusses the potential dual effects of IL-1ra observed in different models, and comments on future directions.Keywords
This publication has 71 references indexed in Scilit:
- Nuclear Receptors as Targets for Drug Development: Crosstalk Between Peroxisome Proliferator-Activated Receptor γ and Cytokines in Bone Marrow-Derived Mesenchymal Stem CellsJournal of Pharmacological Sciences, 2005
- A continuous delivery system of IL‐1 receptor antagonist reduces angiogenesis and inhibits tumor developmentThe FASEB Journal, 2003
- Leptin induces IL-1 receptor antagonist expression in the brainBiochemical and Biophysical Research Communications, 2002
- IL-1ra and IL-1 production in human oral mucosal epithelial cells in culture: differential modulation by TGF-β1 and IL-4Clinical and Experimental Immunology, 2002
- Production of Mice Deficient in Genes for Interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 Receptor Antagonist Shows that IL-1β Is Crucial in Turpentine-induced Fever Development and Glucocorticoid SecretionThe Journal of Experimental Medicine, 1998
- Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseasesEuropean Journal of Gastroenterology & Hepatology, 1995
- Dysregulation of the in vivo production of interleukin‐1 receptor antagonist in patients with rheumatoid arthritis pathogenetic implicationsArthritis & Rheumatism, 1995
- Interleukin-1 Receptor Antagonist Prevents Low-Dose Streptozotocin-Induced Diabetes in MiceBiochemical and Biophysical Research Communications, 1994
- Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha.The Journal of Experimental Medicine, 1992
- Interleukin 1 receptor antagonist in human epidermis and cultured keratinocytesFEBS Letters, 1991